Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

Mario Giuliano(Regione Campania), Daniele Generali(University of Trieste), Fabio Puglisi(University of Udine), Pietro De Placido(University of Naples Federico II), Antonio Giordano(University of Siena), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimo Cristofanilli(Cornell University), Grazia Arpino(University of Naples Federico II), Sergio Venturini(University of Turin), Thomas Bachelot(Centre Léon Bérard), Guglielmo Thomas(Clinica Mediterranea), Carla Rognoni(Bocconi University), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Aleix Prat(Hospital Clínic de Barcelona), Francesco Schettini(Target (United States)), Manuela Milani(Istituti Ospitalieri di Cremona), Barbara Pistilli(Institut Gustave Roussy)
The Lancet Oncology
September 4, 2019
10.1016/s1470-2045(19)30420-6
Cited by 193

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k